Puma Biotechnology Inc Stock Price, News & Analysis

Puma Biotechnology (NASDAQ: PBYI) reported strong Q2 2025 financial results, with product revenue reaching $49.2 million, up from $44.4 million in Q2 2024. The company achieved net income of $5.9 million ($0.12 per share), compared to a net loss of $4.5 million in Q2 2024. Total revenue was $52.4 million, including $3.2 million in royalty revenue.

The company's flagship product NERLYNX® drove year-over-year growth, while operating costs decreased to $45.8 million from $49.3 million. Puma maintains its full-year 2025 guidance of $212-$222 million in total revenue and expects net income between $23-$28 million. The company also reported progress in clinical trials for alisertib in breast and lung cancer, with interim data expected in Q4 2025.

[ "Net income of $5.9 million in Q2 2025, compared to $4.5 million loss in Q2 2024", "Product revenue increased 10.8% to $49.2 million year-over-year", "Operating costs decreased by 7.1% to $45.8 million", "Strong cash position of $96.0 million as of June 30, 2025", "Net cash from operations increased to $14.1 million from $1.0 million in Q2 2024" ]

Puma Biotechnology (NASDAQ: PBYI) has announced it will host a conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET.

Investors can access the call via phone using the dial-in numbers 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on the company's investor relations website. The call recording will be archived on Puma's website for 90 days.

Puma Biotechnology (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for two new non-executive employees. The Compensation Committee approved grants totaling 7,000 shares of Puma common stock on July 1, 2025, under the company's 2017 Employment Inducement Incentive Award Plan.

The restricted stock units will vest over three years, with one-third vesting on July 1, 2026, and one-sixth vesting every six months thereafter, contingent on continued employment. These awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for three new non-executive employees by its Compensation Committee. The awards, totaling 18,250 shares of Puma common stock, were granted under the company's 2017 Employment Inducement Incentive Award Plan. The restricted stock units will vest over three years, with one-third vesting on June 1, 2026, and one-sixth vesting every six months thereafter, contingent on continued employment. These awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology (NASDAQ: PBYI) reported strong Q1 2025 financial results, with net product revenue of $43.1 million from NERLYNX sales, up from $40.3 million in Q1 2024. The company achieved net income of $3.0 million ($0.06 per share), compared to a net loss of $4.8 million in Q1 2024. Total revenue reached $46.0 million, including $2.9 million in royalty revenue. Operating costs decreased to $42.0 million from $46.1 million year-over-year. The company maintains a strong cash position of $93.2 million. Looking ahead, Puma expects Q2 2025 net product revenue of $48-50 million and full-year 2025 net product revenue of $192-198 million, with projected net income of $23-28 million for the year.

Puma Biotechnology (NASDAQ: PBYI) has granted inducement restricted stock unit awards to two new non-executive employees. The awards, approved by the Compensation Committee on May 5, 2025, cover 12,875 shares of Puma common stock. These equity awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan.

The restricted stock units will vest over three years, with one-third vesting on the first anniversary of the vesting commencement dates (April 1, 2025 and May 1, 2025), followed by one-sixth vesting every six months thereafter, contingent on continued employment. The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for the new employees joining Puma.

Puma Biotechnology presented clinical data for neratinib at the AACR Annual Meeting 2025 in Chicago. The Phase I trial (NCI 10495) evaluated the combination of neratinib with trastuzumab deruxtecan in patients with HER2-altered solid tumors.

Key findings from the 20-patient trial:

• Most common side effects: nausea (75%), diarrhea (75%), fatigue (65%)
• 4 patients achieved partial responses, including cases of gastroesophageal, pancreatic, and ovarian cancers
• Notable results in pancreatic cancer: 3 of 5 patients showed tumor shrinkage

The study established Dose Level 3 as the recommended Phase II dose: trastuzumab deruxtecan at 5.4 mg/kg combined with neratinib starting at 120 mg (week 1), increasing to 160 mg (week 2), and 240 mg (week 3 onward). Part 2 of the study, focusing on pharmacodynamic evaluation in 12 patients, began enrollment in March 2025.

Puma Biotechnology (NASDAQ: PBYI) has announced it will host a conference call to discuss its first quarter 2025 financial results on Thursday, May 8, 2025, at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the call through domestic (1-877-709-8150) or international (1-201-689-8354) dial-in numbers.

A live webcast and presentation slides will be available on the Investors section of the company's website. The call recording will be archived on Puma's website for 90 days following the event.

Puma Biotechnology (NASDAQ: PBYI) has announced the approval of inducement restricted stock unit awards for four new non-executive employees. The Compensation Committee approved grants covering 23,875 shares of Puma common stock on April 1, 2025.

The awards, granted under Puma's 2017 Employment Inducement Incentive Award Plan, will vest over three years. One-third of the shares will vest on the first anniversary (April 1, 2025), followed by one-sixth vesting every six months thereafter, contingent on continued employment. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).